Clinical Trials Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Jul 14, 2023; 29(26): 4200-4213
Published online Jul 14, 2023. doi: 10.3748/wjg.v29.i26.4200
Figure 3
Figure 3 Nomogram for the new risk grade model with consideration of raf kinase inhibitory protein and phosphorylated-extracellular-signal regulated kinase to predict the probabilities of 5-yr survival with gastrointestinal stromal tumors. Raf kinase inhibitory protein (RKIP) expression, phosphorylated-extracellular-signal regulated kinase (P-ERK) expression, tumor size, tumor location and mitotic count are involved as assessment factors.